A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: Reduced cyclophosphamide combined with etoposide and total body irradiation

American Journal of Hematology

Volumn 83, Issue 8, 2008, Pages 635-639

  Yoshimi, Akihide ^a   Nannya, Yasuhito ^a   Sakata Yanagimoto, Mamiko ^a   Oshima, Kumi ^a,b   Takahashi, Tsuyoshi ^a   Kanda, Yoshinobu ^a,b   Motokura, Toru ^a   Chiba, Shigeru ^a,b   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLADDER DISEASE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER TOXICITY; LUNG TOXICITY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STOMATITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; COMORBIDITY; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HEART DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 49149102625     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21208     Document Type: Article

References (28)

1. Akahori M, Nakamae H, Hino M, et al. Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant 2003;31:585-590.
2. Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: Risk for cardiac toxicity. Bone Marrow Transplant 1990;5:173-177.
3. Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-1223.
4. Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: Prognostic factors. Bone Marrow Transplant 2000;25:885-894.
5. Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in hematological stem cell transplantation: Predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001;27:307-310.
6. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 1986;68:1114-1118.
7. Hertenstein B, Stefanic M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994;12:998-1004.
8. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 2001;28:283-287.
9. Nakamae H, Tsumura K, Hino M, et al. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000;355:805-806.
10. Arnold R, Massenkeil G, Bornhauser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk all may be effective in early but not in advanced disease. Leukemia 2002;16:2423-2428.
11. Martino R, Giralt S, Caballero MD, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica 2003;88:555-560.
12. Massenkeil G, Nagy M, Lawang M, et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003;31:339-345.
13. Henwood JM, Brogden RN. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990;39:438-490.
14. Giralt SA, LeMaistre CF, Vriesendorp HM, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 1994;12:1923-1930.
15. Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997;3:324-330.
16. Spitzer TR, Cottler-Fox M, Torrisi J, et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989;4: 559-565.
17. Yau JC, LeMaistre CF, Andersson BS, et al. Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. Am J Hematol 1992;41:40-44.
18. Duerst RE, Horan JT, Liesveld JL, et al. Allogeneic bone marrow transplantation for children with acute leukemia: Cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. Bone Marrow Transplant 2000;25:489-494.
19. Schmitz N, Gassmann W, Rister M, et al. Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 1988;72:1567-1573.
20. Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993;82:2920-2928.
21. Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987;69:1015-1020.
22. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577.
23. Bloomfield CD, Archer KJ, Mrozek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: Report from an international workshop. Genes Chromosomes Cancer 2002;33:362-378.
24. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 1994;23:86-98.
25. Sakata-Yanagimoto M, Kanda Y, Nakagawa M, et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:1043-1047.
26. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-1568.
27. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706.